Highest-materiality recent filing
Pelthos Therapeutics dismisses CFO Knuettel, appoints Grant Thornton as auditor
CFO Francis Knuettel II terminated effective April 10, 2026; separation agreement provides $430,000 severance (12 months salary) and accelerated vesting of 59,500 options and 19,525 RSUs.
Pelthos Therapeutics Q1 2026 ZELSUVMI net revenue $10.7M, up 17% QoQ; net loss $10.2M
ZELSUVMI net product revenue $10.7M in Q1 2026, up 17% from $9.1M in Q4 2025; units dispensed 7,884 (+25% QoQ).
Pelthos Q4 ZELSUVMI sales $9.1M, up 28% QoQ; adds XEPI and XEGLYZE
ZELSUVMI net product revenue $9.1M in Q4 2025 vs $7.1M in Q3; full-year 2025 total revenue $16.8M.
Pelthos secures up to $50M senior secured term loan from Horizon; $30M drawn at close
Up to $50M senior secured term loan facility from Horizon Technology Finance; $30M funded at closing on Jan 12, 2026.
Pelthos Q3: ZELSUVMI launch generates $7.1M net revenue, net loss $16.2M
Net product revenue of $7.1M from ZELSUVMI in first commercial quarter (Q3 ended Sep 30, 2025).
Pelthos raises $18M via convertible notes; acquires Xepi from Biofrontera
Issued $18.0M aggregate 8.5% senior secured convertible notes due Nov 2027; conversion price $34.442/sh (adjustable to $29.73 on shareholder approval).
Pelthos (PTHS) files LNHC unaudited financials and pro forma data post-merger closed July 1, 2025
Merger closed July 1, 2025; issued ~31,278 Series A Preferred shares to Ligand; PIPE raised ~$50.1M gross.
Pelthos Therapeutics completes merger, launches ZELSUVMI, hires 50 sales managers
Completed merger with Channel Therapeutics and closed $50.1M private placement on July 1, 2025.
Pelthos Therapeutics closes merger with LNHC, raises $50.1M PIPE
Closed merger with LNHC (Ligand subsidiary) on July 1, 2025; LNHC shareholders own ~55.8% on fully diluted basis.
Channel Therapeutics to merge with LNHC in reverse merger; Ligand to own ~55%
LNHC valued at $67M; Channel at $15M; combined entity renamed Pelthos Therapeutics Inc.
Proposal 4 approved: reincorporation from Delaware to Nevada and renaming to Channel Therapeutics Corp. (2.6M for, 2.3K against, 929.7K abstain).
Chromocell raises $750k via convertible note and secures $30M committed equity facility
$750k convertible note issued, 6% interest (12% default), convertible at $1.506/share, floor $0.231, maturity Aug 24, 2025.
Chromocell updates on $6.6M IPO, pipeline progress, and liability reduction
Closed IPO Feb 21, 2024, gross proceeds ~$6.6M; all pre-IPO debt and Series A preferred converted.
Chromocell launches eye pain program targeting $2.5B market; hires Dr. Simon Chandler
NaV1.7 sodium channel program for eye pain; addresses 5M annual U.S. corneal abrasions.
Chromocell Therapeutics prices IPO at $6.00/share, raises $6.6M gross, lists on NYSE American
Sold 1,100,000 shares at $6.00; gross proceeds ~$6.6M; closed Feb 21, 2024.
the Board terminated Francis Knuettel II from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective April 10, 2026.
The board of directors (the “Board”) of Chromocell Therapeutics Corporation (the “Company”) has appointed Francis Knuettel II as Chief Executive Officer of the Company, effective March 13, 2024.
Max materiality 1.00 · Median 0.55 · Most common event other_material